Amphotericin B cochleates - BioDelivery Sciences

Drug Profile

Amphotericin B cochleates - BioDelivery Sciences

Alternative Names: BioNasal Amphotericin B; Bioral amphotericin B; Bioral Amphotericin B; Encochleated amphotericin B; SinuNase

Latest Information Update: 11 Sep 2013

Price : $50

At a glance

  • Originator BioDelivery Sciences International
  • Developer Accentia Biopharmaceuticals; BioDelivery Sciences International; Drugs for Neglected Diseases Initiative Foundation
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chagas disease; Leishmaniasis; Mycoses; Rhinosinusitis; Sinusitis

Most Recent Events

  • 11 Sep 2013 Discontinued - Phase-III for Sinusitis in USA (Intranasal)
  • 11 Sep 2013 Discontinued - Phase-III for Rhinosinusitis in USA (Intranasal)
  • 11 Sep 2013 Discontinued - Phase-I for Mycoses in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top